Can-Fite BioPharma (CANF) Earnings Date, Estimates & Call Transcripts $1.81 -0.10 (-5.24%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.78 -0.03 (-1.88%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends Get Can-Fite BioPharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Can-Fite BioPharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCANF Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CANF Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Can-Fite BioPharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($1.25) EPSNext Year EPS Consensus Estimate: ($0.05) EPS Can-Fite BioPharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023-$0.27-$0.31 -$0.04-$0.31$0.20M$0.16M11/30/2023Q3 2023-$0.43-$0.43--$0.43$0.20M$0.20M8/31/2023Q2 2023-$0.54-$0.40+$0.14-$0.40$0.20M$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M Get the Latest News and Ratings for CANF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. 6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M6/1/2023Q1 2023--$0.65 -$0.65-$0.65-$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20MWatch This Robotics Demo Before March 17th (Ad)Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." Click here to watch the demo…3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M3/30/2023Q4 2022-$0.57-$1.11 -$0.54-$1.11$0.50M$0.20M Can-Fite BioPharma Earnings - Frequently Asked Questions How much revenue does Can-Fite BioPharma generate each year? Can-Fite BioPharma (NYSE:CANF) has a recorded annual revenue of $740,000.00. How much profit does Can-Fite BioPharma generate each year? Can-Fite BioPharma (NYSE:CANF) has a recorded net income of -$7.63 million. CANF has generated -$1.79 earnings per share over the last four quarters. What is Can-Fite BioPharma's EPS forecast for next year? Can-Fite BioPharma's earnings are expected to grow from ($1.25) per share to ($0.05) per share in the next year. More Earnings Resources from MarketBeat Related Companies NXTC Earnings INAB Earnings LSTA Earnings SNTI Earnings CARM Earnings LPCN Earnings APRE Earnings LPTX Earnings MIRA Earnings OKUR Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? This page (NYSE:CANF) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
